Pulmonary Exacerbations in Cystic Fibrosis

Harvey R. Rabin, Steven M. Butler, Mary Ellen B Wohl, David E. Geller, Andrew Colin, Daniel V. Schidlow, Charles A. Johnson, Michael W. Konstan, Warren E. Regelmann

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

The clinical characteristics most relevant to the decision to treat for a pulmonary exacerbation with antibiotics in cystic fibrosis patients were determined. Variables including age, increased cough frequency and sputum production, new crackles and wheezing, asthma, symptomatic sinusitis, hemoptysis, decreased lung function, weight loss, and new acquisition of Pseudomonas aeruginosa were collected in a large prospective multicenter database (Epidemiologic Study of Cystic Fibrosis). During a 12-month baseline period, data from 11,692 patients were compared with data collected during the subsequent 6-month study period. Because pulmonary function assessments were unavailable for patients <6 years of age, separate analyses were done for those <6 and ≥6 years of age. The outcome of interest was any antibiotic treatment in the 6-month study period reported as indicated for an exacerbation. Characteristics with the most discriminatory power were determined using stepwise multiple logistic regression. For patients <6 years of age, the strongest independent associations with treatment for a pulmonary exacerbation were new crackles, increased cough frequency, decline in weight, and increased sputum production. For those patients ≥6 years of age, the strongest independent associations were a relative decrease in percent predicted forced expired volume in 1 sec, increased cough frequency, new crackles, and hemoptysis. The presence of three or more of these key characteristics was strongly associated with the occurrence of a treated exacerbation. The reproducibility of the model over time was confirmed by application to a subsequent set of data. This model has potential for use as an outcome measure in clinical trials, and to assist in treatment decisions for individual patients.

Original languageEnglish
Pages (from-to)400-406
Number of pages7
JournalPediatric Pulmonology
Volume37
Issue number5
DOIs
StatePublished - May 1 2004
Externally publishedYes

Fingerprint

Cystic Fibrosis
Respiratory Sounds
Lung
Cough
Hemoptysis
Sputum
Anti-Bacterial Agents
Sinusitis
Pseudomonas aeruginosa
Weight Loss
Epidemiologic Studies
Therapeutics
Asthma
Logistic Models
Outcome Assessment (Health Care)
Clinical Trials
Databases
Weights and Measures

Keywords

  • Clinical trials
  • Cystic fibrosis
  • Epidemlologic studies
  • Pulmonary exacerbations

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

Rabin, H. R., Butler, S. M., Wohl, M. E. B., Geller, D. E., Colin, A., Schidlow, D. V., ... Regelmann, W. E. (2004). Pulmonary Exacerbations in Cystic Fibrosis. Pediatric Pulmonology, 37(5), 400-406. https://doi.org/10.1002/ppul.20023

Pulmonary Exacerbations in Cystic Fibrosis. / Rabin, Harvey R.; Butler, Steven M.; Wohl, Mary Ellen B; Geller, David E.; Colin, Andrew; Schidlow, Daniel V.; Johnson, Charles A.; Konstan, Michael W.; Regelmann, Warren E.

In: Pediatric Pulmonology, Vol. 37, No. 5, 01.05.2004, p. 400-406.

Research output: Contribution to journalArticle

Rabin, HR, Butler, SM, Wohl, MEB, Geller, DE, Colin, A, Schidlow, DV, Johnson, CA, Konstan, MW & Regelmann, WE 2004, 'Pulmonary Exacerbations in Cystic Fibrosis', Pediatric Pulmonology, vol. 37, no. 5, pp. 400-406. https://doi.org/10.1002/ppul.20023
Rabin HR, Butler SM, Wohl MEB, Geller DE, Colin A, Schidlow DV et al. Pulmonary Exacerbations in Cystic Fibrosis. Pediatric Pulmonology. 2004 May 1;37(5):400-406. https://doi.org/10.1002/ppul.20023
Rabin, Harvey R. ; Butler, Steven M. ; Wohl, Mary Ellen B ; Geller, David E. ; Colin, Andrew ; Schidlow, Daniel V. ; Johnson, Charles A. ; Konstan, Michael W. ; Regelmann, Warren E. / Pulmonary Exacerbations in Cystic Fibrosis. In: Pediatric Pulmonology. 2004 ; Vol. 37, No. 5. pp. 400-406.
@article{82e2a9725b664b38b69b88ef1e65cb8a,
title = "Pulmonary Exacerbations in Cystic Fibrosis",
abstract = "The clinical characteristics most relevant to the decision to treat for a pulmonary exacerbation with antibiotics in cystic fibrosis patients were determined. Variables including age, increased cough frequency and sputum production, new crackles and wheezing, asthma, symptomatic sinusitis, hemoptysis, decreased lung function, weight loss, and new acquisition of Pseudomonas aeruginosa were collected in a large prospective multicenter database (Epidemiologic Study of Cystic Fibrosis). During a 12-month baseline period, data from 11,692 patients were compared with data collected during the subsequent 6-month study period. Because pulmonary function assessments were unavailable for patients <6 years of age, separate analyses were done for those <6 and ≥6 years of age. The outcome of interest was any antibiotic treatment in the 6-month study period reported as indicated for an exacerbation. Characteristics with the most discriminatory power were determined using stepwise multiple logistic regression. For patients <6 years of age, the strongest independent associations with treatment for a pulmonary exacerbation were new crackles, increased cough frequency, decline in weight, and increased sputum production. For those patients ≥6 years of age, the strongest independent associations were a relative decrease in percent predicted forced expired volume in 1 sec, increased cough frequency, new crackles, and hemoptysis. The presence of three or more of these key characteristics was strongly associated with the occurrence of a treated exacerbation. The reproducibility of the model over time was confirmed by application to a subsequent set of data. This model has potential for use as an outcome measure in clinical trials, and to assist in treatment decisions for individual patients.",
keywords = "Clinical trials, Cystic fibrosis, Epidemlologic studies, Pulmonary exacerbations",
author = "Rabin, {Harvey R.} and Butler, {Steven M.} and Wohl, {Mary Ellen B} and Geller, {David E.} and Andrew Colin and Schidlow, {Daniel V.} and Johnson, {Charles A.} and Konstan, {Michael W.} and Regelmann, {Warren E.}",
year = "2004",
month = "5",
day = "1",
doi = "10.1002/ppul.20023",
language = "English",
volume = "37",
pages = "400--406",
journal = "Pediatric Pulmonology",
issn = "8755-6863",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Pulmonary Exacerbations in Cystic Fibrosis

AU - Rabin, Harvey R.

AU - Butler, Steven M.

AU - Wohl, Mary Ellen B

AU - Geller, David E.

AU - Colin, Andrew

AU - Schidlow, Daniel V.

AU - Johnson, Charles A.

AU - Konstan, Michael W.

AU - Regelmann, Warren E.

PY - 2004/5/1

Y1 - 2004/5/1

N2 - The clinical characteristics most relevant to the decision to treat for a pulmonary exacerbation with antibiotics in cystic fibrosis patients were determined. Variables including age, increased cough frequency and sputum production, new crackles and wheezing, asthma, symptomatic sinusitis, hemoptysis, decreased lung function, weight loss, and new acquisition of Pseudomonas aeruginosa were collected in a large prospective multicenter database (Epidemiologic Study of Cystic Fibrosis). During a 12-month baseline period, data from 11,692 patients were compared with data collected during the subsequent 6-month study period. Because pulmonary function assessments were unavailable for patients <6 years of age, separate analyses were done for those <6 and ≥6 years of age. The outcome of interest was any antibiotic treatment in the 6-month study period reported as indicated for an exacerbation. Characteristics with the most discriminatory power were determined using stepwise multiple logistic regression. For patients <6 years of age, the strongest independent associations with treatment for a pulmonary exacerbation were new crackles, increased cough frequency, decline in weight, and increased sputum production. For those patients ≥6 years of age, the strongest independent associations were a relative decrease in percent predicted forced expired volume in 1 sec, increased cough frequency, new crackles, and hemoptysis. The presence of three or more of these key characteristics was strongly associated with the occurrence of a treated exacerbation. The reproducibility of the model over time was confirmed by application to a subsequent set of data. This model has potential for use as an outcome measure in clinical trials, and to assist in treatment decisions for individual patients.

AB - The clinical characteristics most relevant to the decision to treat for a pulmonary exacerbation with antibiotics in cystic fibrosis patients were determined. Variables including age, increased cough frequency and sputum production, new crackles and wheezing, asthma, symptomatic sinusitis, hemoptysis, decreased lung function, weight loss, and new acquisition of Pseudomonas aeruginosa were collected in a large prospective multicenter database (Epidemiologic Study of Cystic Fibrosis). During a 12-month baseline period, data from 11,692 patients were compared with data collected during the subsequent 6-month study period. Because pulmonary function assessments were unavailable for patients <6 years of age, separate analyses were done for those <6 and ≥6 years of age. The outcome of interest was any antibiotic treatment in the 6-month study period reported as indicated for an exacerbation. Characteristics with the most discriminatory power were determined using stepwise multiple logistic regression. For patients <6 years of age, the strongest independent associations with treatment for a pulmonary exacerbation were new crackles, increased cough frequency, decline in weight, and increased sputum production. For those patients ≥6 years of age, the strongest independent associations were a relative decrease in percent predicted forced expired volume in 1 sec, increased cough frequency, new crackles, and hemoptysis. The presence of three or more of these key characteristics was strongly associated with the occurrence of a treated exacerbation. The reproducibility of the model over time was confirmed by application to a subsequent set of data. This model has potential for use as an outcome measure in clinical trials, and to assist in treatment decisions for individual patients.

KW - Clinical trials

KW - Cystic fibrosis

KW - Epidemlologic studies

KW - Pulmonary exacerbations

UR - http://www.scopus.com/inward/record.url?scp=2442480846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442480846&partnerID=8YFLogxK

U2 - 10.1002/ppul.20023

DO - 10.1002/ppul.20023

M3 - Article

C2 - 15095322

AN - SCOPUS:2442480846

VL - 37

SP - 400

EP - 406

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

SN - 8755-6863

IS - 5

ER -